Get the Stockscreener App
14.09
4.05%
-0.595
Travere Therapeutics Inc stock is traded at $14.09, with a volume of 1.34M.
It is down -4.05% in the last 24 hours and down -16.16% over the past month.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.
See More
Previous Close:
$14.68
Open:
$14.51
24h Volume:
1.34M
Relative Volume:
0.77
Market Cap:
$1.34B
Revenue:
$203.45M
Net Income/Loss:
$-351.45M
P/E Ratio:
-3.0956
EPS:
-4.55
Net Cash Flow:
$-369.41M
1W Performance:
-6.91%
1M Performance:
-16.16%
6M Performance:
-17.82%
1Y Performance:
+92.16%
1-Day Range:
$14.01
$14.60
1-Week Range:
$14.01
$15.51
52-Week Range:
$6.80
$25.29
Travere Therapeutics Inc Stock (TVTX) Company Profile
Name
Travere Therapeutics Inc
Sector
Industry
Phone
888-969-7879
Address
3611 VALLEY CENTRE DR, SAN DIEGO
Compare TVTX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TVTX
Travere Therapeutics Inc
|
14.09 | 1.34B | 203.45M | -351.45M | -369.41M | -4.55 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.99 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
508.86 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.71 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
540.71 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
254.09 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Travere Therapeutics Inc Stock (TVTX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jun-11-25 | Reiterated | Citigroup | Buy |
| Jun-11-25 | Resumed | H.C. Wainwright | Buy |
| Jan-10-25 | Initiated | Cantor Fitzgerald | Overweight |
| Oct-21-24 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Sep-09-24 | Upgrade | Guggenheim | Neutral → Buy |
| Mar-27-24 | Downgrade | Guggenheim | Buy → Neutral |
| Dec-05-23 | Upgrade | Citigroup | Neutral → Buy |
| Nov-20-23 | Initiated | Citigroup | Neutral |
| Sep-22-23 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-21-23 | Downgrade | William Blair | Outperform → Mkt Perform |
| Sep-06-23 | Resumed | Evercore ISI | Outperform |
| Jul-21-23 | Initiated | JP Morgan | Overweight |
| Jun-07-23 | Resumed | Piper Sandler | Neutral |
| May-22-23 | Initiated | TD Cowen | Outperform |
| May-05-23 | Upgrade | Bryan Garnier | Sell → Neutral |
| Mar-01-23 | Initiated | Guggenheim | Buy |
| Feb-21-23 | Upgrade | Wedbush | Neutral → Outperform |
| Dec-14-22 | Initiated | Stifel | Hold |
| Dec-05-22 | Initiated | Wells Fargo | Overweight |
| Sep-21-22 | Initiated | Bryan Garnier | Sell |
| Jul-14-22 | Resumed | Canaccord Genuity | Buy |
| Mar-31-22 | Initiated | Piper Sandler | Overweight |
| Feb-28-22 | Initiated | H.C. Wainwright | Buy |
| May-26-21 | Downgrade | Wedbush | Outperform → Neutral |
View All
Travere Therapeutics Inc Stock (TVTX) Latest News
(TVTX) On The My Stocks Page - news.stocktradersdaily.com
Rhumbline Advisers Grows Stock Holdings in Travere Therapeutics, Inc. (NASDAQ:TVTX) - Defense World
What is HC Wainwright’s Estimate for TVTX Q2 Earnings? - Defense World
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere ... - Eagle-Tribune
Travere Therapeutics Launches "Play It Forward" Campaign to Celebrate the FSGS Community on Inaugural Awareness Day - Black Hills Pioneer
HC Wainwright Starts Travere Therapeutics, Inc. (TVTX) at Buy on FILSPARI Breakthroughs - MSN
Leerink Partnrs Has Negative Outlook for TVTX Q4 Earnings - Defense World
Travere Therapeutics’ SWOT analysis: rare disease stock faces regulatory hurdles - Investing.com Canada
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | TVTX Stock News - GuruFocus
Citigroup Issues Pessimistic Forecast for Travere Therapeutics (NASDAQ:TVTX) Stock Price - Defense World
Travere Therapeutics (NASDAQ:TVTX) Stock Rating Upgraded by HC Wainwright - Defense World
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)June 12, 2025 - BioSpace
10 Best Growth Stocks Under $100 to Buy Now - Insider Monkey
Travere Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - marketscreener.com
Travere Therapeutics Inc (TVTX) Has Recovered 53.17% From Its Low: Is This The Beginning Of A Trend? - Stocksregister
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Travere Therapeutics, Inc.TVTX - WV News
Travere Therapeutics (TVTX) Price Target Lowered by Citigroup | - GuruFocus
Citi Adjusts Price Target and Maintains Buy Rating on Travere Th - GuruFocus
Travere Therapeutics (TVTX) Receives Buy Rating from HC Wainwrig - GuruFocus
Travere Therapeutics (TVTX) Receives Buy Rating from HC Wainwright & Co. | TVTX Stock News - GuruFocus
7 Analysts Assess Travere Therapeutics: What You Need To Know - Nasdaq
Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the 15th International Podocyte Conference | TVTX Stock News - GuruFocus
Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the 15th International Podocyte Conference - Eagle-Tribune
H.C. Wainwright Initiates Coverage on Travere Therapeutics (TVTX) with Optimistic Outlook | TVTX Stock News - GuruFocus
Travere Therapeutics (TVTX) Sees Price Target Adjustment with Ne - GuruFocus
Citi Adjusts Price Target and Maintains Buy Rating on Travere Therapeutics (TVTX) | TVTX Stock News - GuruFocus
Travere Therapeutics Clears Key Benchmark, Hitting 80-Plus RS Rating - Investor's Business Daily
Travere Therapeutics Launches "Play It Forward" Campaign to Cele - GuruFocus
Travere Therapeutics, Inc. (NASDAQ:TVTX) Stake Boosted by California State Teachers Retirement System - Defense World
Wellington Management Group LLP Invests $583,000 in Travere Therapeutics, Inc. (NASDAQ:TVTX) - Defense World
Squarepoint Ops LLC Sells 11,006 Shares of Travere Therapeutics, Inc. (NASDAQ:TVTX) - Defense World
Transcript : Travere Therapeutics, Inc. Presents at Jefferies Global Healthcare Conference 2025, Jun-04-2025 03 - marketscreener.com
Travere Therapeutics, Inc. (NASDAQ:TVTX) Shares Sold by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
IgA Nephropathy Market Forecast 2034: Clinical Trials, EMA, PDMA, FDA Approval, Treatment Market, Revenue, Statistics, Therapies, and Companies by DelveInsight - The Globe and Mail
When (TVTX) Moves Investors should Listen - news.stocktradersdaily.com
Travere Therapeutics, Inc. (TVTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the 62nd ERA Congress - BioSpace
Travere Therapeutics to Present New FILSPARI® (sparsentan) Data at the 62nd ERA Congress | TVTX Stock News - GuruFocus
Bronstein, Gewirtz & Grossman, LLC Encourages Travere Therapeutics, Inc. (TVTX) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Is Investigating Travere Therapeutics, Inc. (TVTX) And Encourages Shareholders to Connect - ACCESS Newswire
2025-06-01 | Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Travere Therapeutics, Inc. (TVTX) And Encourages Shareholders to Reach Out | NDAQ:TVTX | Press Release - Stockhouse
Levi & Korsinsky Launches Fraud Investigation on Behalf of Travere Therapeutics, Inc. (TVTX) Shareholders - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Travere Therapeutics, Inc. (TVTX) and Encourages Investors to Learn More About the Investigation - ACCESS Newswire
Would Travere Therapeutics (NASDAQ:TVTX) Be Better Off With Less Debt? - simplywall.st
Lost Money on Travere Therapeutics, Inc. (TVTX)? Possible FraudContact Levi & Korsinsky Today - ACCESS Newswire
Travere Therapeutics, Inc. (TVTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Travere Therapeutics, Inc. (NASDAQ:TVTX) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Bronstein, Gewirtz & Grossman, LLC Is Investigating Travere Therapeutics, Inc. (TVTX) And Encourages Investors to Connect - ACCESS Newswire
TVTX Investor Notice: Levi & Korsinsky Investigates Travere Therapeutics, Inc. for Securities Law Violations - Louisiana First News
FILSPARI to Transform Kidney Disease Care with Its Revolutionary Treatment Approach | DelveInsight - The Malaysian Reserve
Travere Therapeutics, Inc. (NASDAQ:TVTX) Shares Purchased by MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. - Defense World
Travere Therapeutics Inc Stock (TVTX) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.63%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):